Grund Nicholas's Form 4 filing
Akebia Therapeutics, Inc.AKBA · filed Feb 4, 2026
- Accession no.
- 0001661887-26-000002
- Filed
- Feb 4, 2026
- Trade date
- Feb 2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $117.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Grund NicholasCIK 0001661887 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Common Stock | SSaleDisposed | −53,585 | $1.39 | −$74,483.15 | 592,994 | Direct | |
| Feb 2, 2026 | Common Stock | SSaleDisposed | −31,244 | $1.39 | −$43,429.16 | 561,750 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.